Adial Pharmaceuticals shares are trading higher after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals shares are trading higher after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.
July 23, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals shares are trading higher following the announcement of progress in the Pharmacokinetics Study of AD04 for alcohol use disorder.
The advancement into the second cohort and commencement of dosing for the Pharmacokinetics Study of AD04 is a positive development for Adial Pharmaceuticals, indicating progress in their clinical trials. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100